Optimization of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin therapy for Japanese patients with urothelial carcinomaTaketo Kawai, Haruki Kume, Jimpei Miyakawa et al.|Japanese Journal of Clinical Oncology|2025Cited by 7
Physical, but not laboratory, treatment‐related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysisSatoru Taguchi, Haruki Kume, Taketo Kawai et al.|International Journal of Urology|2024Cited by 4
The first real-world evidence on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin followed by switch maintenance avelumab in advanced urothelial carcinoma: a propensity score-matched studySatoru Taguchi, Haruki Kume, Taketo Kawai et al.|International Journal of Clinical Oncology|2025Cited by 3
Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysisSatoru Taguchi, Haruki Kume, Taketo Kawai et al.|Research Square|2024Cited by 2